INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2015

Glucosamine and chondroitin use was not linked to symptom relief or reduced disease progression in patients with knee osteoarthritis.

Researchers analyzed 4-year follow-up data from 1,625 patients with knee osteoarthritis from the Osteoarthritis Initiative using a new-user design and marginal structural models. During follow-up, 18% of participants initiated treatment. Compared to never-users, users of glucosamine/chondroitin at all assessments showed no clinically significant differences in WOMAC pain (β = 0.68 [95% CI -0.16 to 1.53]), WOMAC stiffness (β = 0.41 [95% CI 0 to 0.82]), WOMAC function (β = 1.28 [95% CI -1.23 to 3.79]), or joint space width (β = 0.11 [95% CI -0.21 to 0.44]).

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study using marginal structural models
Who was studied
1,625 participants with knee osteoarthritis from the Osteoarthritis Initiative not using glucosamine/chondroitin at baseline
What was measured
WOMAC pain, stiffness, and function, and joint space width (JSW)

THE PAPER

Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: an analysis with marginal structural models.

Yang S, Eaton CB, McAlindon TE, Lapane KL. Arthritis Rheumatol, 2015.

PubMed 25369761 ↗DOI 10.1136/annrheumdis-2013-203954 ↗

Bones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.